ITACA NSCLC study: Final results
Prof Silvia Novello - University of Turin, Turin, Italy
16 Feb 2021
KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated...
Prof Michael Boyer - Chris O’Brien Lifehouse, Sydney, Australia
16 Feb 2021
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
9 Feb 2021
Latest in EGFR-positive NSCLC with exon 20 insertion mutations
Prof Sanjay Popat, Prof Michael Thomas, Dr Marina Garassino, Dr Rosario Campelo,...
9 Feb 2021
WCLC 2020 overview
Dr Luis Raez - Memorial Healthcare System, Hollywood, FL, USA
5 Feb 2021
OncoAlert and ecancer weekly roundup for January 25 - 31, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
4 Feb 2021
WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with ...
Dr Joshua Bauml and Dr Joshua Sabari
3 Feb 2021
New data from rare EGFR alterations in NSCLC from WCLC 2020 virtual meeting
Prof Tony Mok - Chinese University of Hong Kong, Shatin, Hong Kong
2 Feb 2021
The role of immune checkpoint inhibitors in NSCLC
Dr Maurice Pérol, Centre Léon Bérard, Lyon, France
27 Jan 2021
OncoAlert and ecancer weekly roundup for January 18 - 24, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
25 Jan 2021
Ferroptosis regulator as a novel therapeutic target for STK11/KEAP1 co-mutant lu...
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York, USA
20 Jan 2021
